18F‑Pentixafor PET/MR and cardiac MRI to check heart microcirculation after a first heart attack
Multimodal Imaging Assessment After Revascularization in Patients With Acute Myocardial Infarction
This will test whether 18F‑Pentixafor PET/MR plus cardiac MRI can reveal small‑vessel injury and recovery in people who had a first heart attack treated with emergency PCI.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | The Affiliated Hospital of Qingdao University Academic / other |
| Locations | 1 site (Qingdao, Shandong) |
| Trial ID | NCT07130409 on ClinicalTrials.gov |
What this trial studies
This prospective cohort will enroll 20 patients with a first acute myocardial infarction who underwent emergency PCI at The Affiliated Hospital of Qingdao University. Participants will receive baseline cardiac MRI within 7 days after PCI, an 18F‑Pentixafor PET/MR examination, routine laboratory tests and ECG, and a follow-up cardiac MRI at six months. Imaging will be read blindly by at least two specialist physicians in radiology and nuclear medicine, and clinical, laboratory, and imaging data will be integrated to characterize coronary microcirculatory function and myocardial recovery. The protocol is observational and does not assign investigational treatments.
Who should consider this trial
Good fit: Adults with a first‑time acute myocardial infarction who received emergency PCI, have complete baseline data, and can safely undergo MRI are ideal candidates.
Not a fit: Patients with prior myocardial infarction or coronary revascularization, severe unstable cardiac or systemic disease, or contraindications to MRI are unlikely to benefit or be eligible.
Why it matters
Potential benefit: If successful, this imaging approach could help clinicians detect microvascular damage earlier and better predict heart recovery after a heart attack.
How similar studies have performed: Small prior studies using CXCR4‑targeted tracers such as 18F‑Pentixafor in post‑infarction imaging have shown promising signals, but broader clinical validation remains limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with a clinical diagnosis of first-episode acute myocardial infarction (AMI) who underwent emergency percutaneous coronary intervention (PCI) were included. All patients had complete baseline clinical data, with baseline cardiac magnetic resonance (CMR) examinations performed within 7 days post-PCI and follow-up CMR completed at 6 months post-procedure. Exclusion Criteria: * Patients with severe cardiac decompensation (Killip class 4) or clinically unstable conditions. Patients with coexisting valvular heart disease, congenital heart disease, pulmonary hypertension, cardiomyopathy, or persistent atrial fibrillation that may confound cardiac structural/functional assessments. Prior history of myocardial infarction, coronary revascularization (PCI/CABG). Concurrent severe systemic diseases including hematologic disorders, malignancies, rheumatic/autoimmune diseases, or severe hepatic/renal failure. Contraindications to CMR (claustrophobia, pacemaker implantation, etc.). Pregnant, breastfeeding, or women of childbearing potential without effective contraception. Sexually active individuals of reproductive age unwilling to use reliable contraception.
Where this trial is running
Qingdao, Shandong
- The Affiliated Hospital of Qingdao University — Qingdao, Shandong, China (Recruiting)
Study contacts
- Study coordinator: Pei Nie, MD
- Email: niepei@qdu.edu.cn
- Phone: 0532-82911500
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.